Trial Profile
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Alectinib; Bevacizumab; Cabozantinib; Cobimetinib; Emactuzumab; Enzalutamide; Erlotinib; Niraparib; Paclitaxel; Pembrolizumab; Pemetrexed; Rucaparib; Simlukafusp alfa; Sunitinib; Vemurafenib; Venetoclax
- Indications Advanced breast cancer; Cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms IMbrella B
- Sponsors Chugai Pharmaceutical; Roche
- 15 Mar 2024 This trial has been completed in Denmark.
- 26 Nov 2023 This trial has been completed in Slovenia, according to European Clinical Trials Database record.
- 07 Nov 2023 Number of treatment arms are increased from 1 to 3 by the addition of Experimental: Combined Agents with Atezolizumab and active comparator arms. New drugs are added to experimental arm (Rucaparib, simlukafusp alfa, Cabozantinib, Emactuzumab) and comparator arm (Vemurafenib, Niraparib) are added. Study design is changed from single group assignment to parallel.